A Potent Bispecific

Pieris Pharmaceuticals’ leading immuno-oncology asset, cinrebafusp alfa (PRS-343), is a bispecific fusion protein that combines a 4-1BB-targeting Anticalin® protein and a HER2-targeting antibody. 4-1BB is an immunoreceptor that powerfully enhances T cell proliferation, survival, and activity. 

Cinrebafusp alfa bridges 4-1BB immune cells with HER2-expressing tumor cells, causing the immune cells to cluster around cancerous cells. By combining a 4-1BB-targeting Anticalin proteinwith a HER2-targeting antibody, cinrebafusp alfa focuses 4-1BB activation locally on the tumor, increasing the efficiency of the immune response and reducing systemic toxicity, compared to 4-1BB-targeting antibodies alone. 

Cinrebafusp alfa has shown both clinical benefit linked to a 4-1BB mechanism of action, and robust durability, and has been observed to be safe and well-tolerated at all doses and schedules tested.

Cinrebafusp Alfa’s Mechanism of Action

Pipeline Chart

Immuno-Oncology

Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate Cinrebafusp Alfa (PRS-343)
Targets

HER2/4-1BB

Partner

n/a

Commercial Rights

Worldwide

Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started

Cinrebafusp Alfa at a Glance

Function/MOA

Tumor-targeted 4-1BB agonism and HER2 antagonism

Indications

HER2-high and HER2-low gastric cancer

Development

Initiating phase 2 in 2021

Commercial Rights

Fully proprietary